Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy.

Akalu YT, Rothlin CV, Ghosh S.

Immunol Rev. 2017 Mar;276(1):165-177. doi: 10.1111/imr.12522. Review.

PMID:
28258690
2.

Protein signatures as potential surrogate biomarkers for stratification and prediction of treatment response in chronic myeloid leukemia patients.

Alaiya AA, Aljurf M, Shinwari Z, Almohareb F, Malhan H, Alzahrani H, Owaidah T, Fox J, Alsharif F, Mohamed SY, Rasheed W, Aldawsari G, Hanbali A, Ahmed SO, Chaudhri N.

Int J Oncol. 2016 Sep;49(3):913-33. doi: 10.3892/ijo.2016.3618. Epub 2016 Jul 7.

3.

TAM receptors Tyro3 and Mer as novel targets in colorectal cancer.

Schmitz R, Valls AF, Yerbes R, von Richter S, Kahlert C, Loges S, Weitz J, Schneider M, Ruiz de Almodovar C, Ulrich A, Schmidt T.

Oncotarget. 2016 Aug 30;7(35):56355-56370. doi: 10.18632/oncotarget.10889.

4.

Phenotypic screening with primary neurons to identify drug targets for regeneration and degeneration.

Cooper DJ, Zunino G, Bixby JL, Lemmon VP.

Mol Cell Neurosci. 2017 Apr;80:161-169. doi: 10.1016/j.mcn.2016.07.001. Epub 2016 Jul 18. Review.

PMID:
27444126
5.

The transcription factor RUNX2 regulates receptor tyrosine kinase expression in melanoma.

Boregowda RK, Medina DJ, Markert E, Bryan MA, Chen W, Chen S, Rabkin A, Vido MJ, Gunderson SI, Chekmareva M, Foran DJ, Lasfar A, Goydos JS, Cohen-Solal KA.

Oncotarget. 2016 May 17;7(20):29689-707. doi: 10.18632/oncotarget.8822.

6.

Genome-wide transcriptome analysis of human epidermal melanocytes.

Haltaufderhyde KD, Oancea E.

Genomics. 2014 Dec;104(6 Pt B):482-9. doi: 10.1016/j.ygeno.2014.09.010. Epub 2014 Oct 30.

7.

MITF in melanoma: mechanisms behind its expression and activity.

Hartman ML, Czyz M.

Cell Mol Life Sci. 2015 Apr;72(7):1249-60. doi: 10.1007/s00018-014-1791-0. Epub 2014 Nov 30. Review.

8.

Kaliziri extract upregulates tyrosinase, TRP-1, TRP-2 and MITF expression in murine B16 melanoma cells.

Tuerxuntayi A, Liu YQ, Tulake A, Kabas M, Eblimit A, Aisa HA.

BMC Complement Altern Med. 2014 May 22;14:166. doi: 10.1186/1472-6882-14-166.

9.
10.

Pathways and therapeutic targets in melanoma.

Shtivelman E, Davies MQ, Hwu P, Yang J, Lotem M, Oren M, Flaherty KT, Fisher DE.

Oncotarget. 2014 Apr 15;5(7):1701-52. Review.

11.

Biology of the TAM receptors.

Lemke G.

Cold Spring Harb Perspect Biol. 2013 Nov 1;5(11):a009076. doi: 10.1101/cshperspect.a009076. Review.

12.

MERTK controls melanoma cell migration and survival and differentially regulates cell behavior relative to AXL.

Tworkoski KA, Platt JT, Bacchiocchi A, Bosenberg M, Boggon TJ, Stern DF.

Pigment Cell Melanoma Res. 2013 Jul;26(4):527-41. doi: 10.1111/pcmr.12110. Epub 2013 May 21.

13.

MERTK receptor tyrosine kinase is a therapeutic target in melanoma.

Schlegel J, Sambade MJ, Sather S, Moschos SJ, Tan AC, Winges A, DeRyckere D, Carson CC, Trembath DG, Tentler JJ, Eckhardt SG, Kuan PF, Hamilton RL, Duncan LM, Miller CR, Nikolaishvili-Feinberg N, Midkiff BR, Liu J, Zhang W, Yang C, Wang X, Frye SV, Earp HS, Shields JM, Graham DK.

J Clin Invest. 2013 May;123(5):2257-67. doi: 10.1172/JCI67816. Epub 2013 Apr 15.

14.

Ribonucleotide reductase and thymidylate synthase or exogenous deoxyribonucleosides reduce DNA damage and senescence caused by C-MYC depletion.

Mannava S, Moparthy KC, Wheeler LJ, Leonova KI, Wawrzyniak JA, Bianchi-Smiraglia A, Berman AE, Flanagan S, Shewach DS, Zeitouni NC, Gudkov AV, Mathews CK, Nikiforov MA.

Aging (Albany NY). 2012 Dec;4(12):917-22.

15.

Cross-phosphorylation, signaling and proliferative functions of the Tyro3 and Axl receptors in Rat2 cells.

Brown JE, Krodel M, Pazos M, Lai C, Prieto AL.

PLoS One. 2012;7(5):e36800. doi: 10.1371/journal.pone.0036800. Epub 2012 May 14.

16.

Phosphoproteomic screen identifies potential therapeutic targets in melanoma.

Tworkoski K, Singhal G, Szpakowski S, Zito CI, Bacchiocchi A, Muthusamy V, Bosenberg M, Krauthammer M, Halaban R, Stern DF.

Mol Cancer Res. 2011 Jun;9(6):801-12. doi: 10.1158/1541-7786.MCR-10-0512. Epub 2011 Apr 26.

17.

Pathways of oncogene-induced senescence in human melanocytic cells.

Bansal R, Nikiforov MA.

Cell Cycle. 2010 Jul 15;9(14):2782-8. Epub 2010 Jul 3. Review. No abstract available.

18.

Sox proteins in melanocyte development and melanoma.

Harris ML, Baxter LL, Loftus SK, Pavan WJ.

Pigment Cell Melanoma Res. 2010 Aug;23(4):496-513. doi: 10.1111/j.1755-148X.2010.00711.x. Epub 2010 Apr 22. Review.

Supplemental Content

Support Center